The U.S. president may have been right, as a recent test believes that a drug he recommended may help in the fight against the Coronavirus.
A substantial new study found that hydroxychloroquine, a drug used to fight malaria, helped several patients with Covid-19 survive.
In fact, the Henry Ford Health System study in Michigan said the drug “significantly” reduced the death rate of patients.
“Treatment with hydroxychloroquine cut the death rate significantly in sick patients hospitalized with COVID-19 – and without heart-related side-effects,” according to a new study published by Henry Ford Health System.
In order to obtain these results, the analysis was tested on at least 2,500 patients infected with Covid-19.
And it is believed that the drug can be effective if patients receive it early in their treatment.
INTERESTING ARTICLE: China detects new respiratory virus with ‘great potential’ to become a pandemic
Supporting President Trump’s statements
“Our analysis shows that using hydroxychloroquine helped save lives,” said Dr. Steven Kalkanis, a neurosurgeon, CEO of the Henry Ford Medical Group.
“As doctors and scientists, we look to the data for insight. And the data here is clear that there was benefit to using the drug as a treatment for sick, hospitalized
Donald Trump, the US chief executive officer, recommended the drug from the beginning as an experimental treatment.
According to CBN News, shortly after his statements, some studies found conflicting results about its effectiveness.
Later, one of those studies that found negative and unfavorable results was withdrawn.
A successful study
Scientists at the Henry Ford Health System explained why their study was successful.
“The findings have been highly analyzed and peer-reviewed,” said Dr. Marcus Zervos, division head of Infectious Disease for Henry Ford Health System
“We attribute our findings that differ from other studies to early treatment, and part of a combination of interventions that were done in supportive care of patients, including careful cardiac monitoring. Our dosing also differed from other studies not showing a benefit of the drug.”
“And other studies are either not peer reviewed, have limited numbers of patients, different patient populations or other differences from our patients,” he concluded.